Vericiguat
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 495 publications
Intrarenal venous flow improvement after vericiguat in worsening HFrEF: indirect effect from improvements in cardiac hemodynamics or possible pleiotropic effect?
Journal: International journal of cardiology
Published: August 24, 2026
Vericiguat in heart failure with reduced ejection fraction: toward a new paradigm of residual risk and worsening heart failure
Journal: Giornale italiano di cardiologia (2006)
Published: July 29, 2026
Wenxin Keli, Clopidogrel, Vericiguat and New Impact Factor: 2.1.
Journal: Anatolian journal of cardiology
Published: July 27, 2026
Vericiguat for the treatment of coronary vasospasm (ViVA): a double-blind placebo-controlled randomized cross-over trial.
Journal: Journal of the American College of Cardiology
Published: July 21, 2026
Beyond the primary endpoint: what VICTOR really tells us about vericiguat.
Journal: Expert opinion on pharmacotherapy
Published: July 11, 2026
Efficacy of Vericiguat by Background Guideline-Directed Medical Therapy in the VICTOR Trial.
Journal: European journal of heart failure
Published: July 10, 2026
History of worsening heart failure and outcomes with vericiguat in ambulatory HFrEF: an exploratory post-hoc analysis of VICTOR.
Journal: European journal of heart failure
Published: July 10, 2026
Soluble guanylate cyclase stimulators and activators: Chemistry, biology, and therapeutic advances.
Journal: European journal of medicinal chemistry
Published: July 05, 2026
Vericiguat for heart failure with reduced ejection fraction: a perspective from approval to real-world clinical treatment.
Journal: Expert review of cardiovascular therapy
Published: June 29, 2026
Effects of Vericiguat on Peripheral Vascular Function and Resting/Exercise Hemodynamics in Patients With Heart Failure With Reduced Ejection Fraction: An Exploratory Pilot Study.
Journal: Journal of cardiovascular pharmacology and therapeutics
Published: June 23, 2026
Vericiguat for heart failure with reduced ejection fraction on quadruple therapy without recent worsening heart failure: an exploratory real-world cohort study.
Journal: BMC cardiovascular disorders
Published: June 09, 2026
Last Updated: 09/26/2026